Mitoxantrone in the treatment of acute myelogenous leukemia: A review

Hematology and Cell Therapy

Volumn 39, Issue 4, 1997, Pages 163-174

  Thomas, X ^a   Archimbaud, E ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Acute myelogenous leukemia; Chemotherapy; Intercalating agents; Mitoxantrone

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CROSS TOLERANCE; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; MUCOSA INFLAMMATION; REVIEW;

EID: 0030866571     PISSN: 12693286     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00282-997-0163-8     Document Type: Review

References (102)

1. Alberts DS, Peng YM, Bowden GT (1985) Pharmacology of mitoxantrone: Mode of action and pharmacokinetics. Invest New Drugs 3: 101-108
2. Amadori S, Arcese W, Isacchi G, et al. (1991) Mitoxantrone, etoposide and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol 9: 1210-1214
3. Amrein PC, Davis RB, Mayer RJ, et al. (1990) Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: A CALGB phase I study. Am J Hematol 35: 80-83
4. Anderson KC, Garnick MB, Meshad MW, et al. (1983) Phase I trial of mitoxantrone by 24-hour continuous infusion. Cancer Treat Rep 67: 435-438
5. Archimbaud E, Leblond V, Michallet M, et al. (1991) Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for resistant or relapsing acute myelogenous leukemia. Blood 77: 1894-1900
6. Archimbaud E, Thomas X, Leblond V, et al. (1995) Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine- 86 trial. J Clin Oncol 13: 11-18
7. Archimbaud E, Leblond V, Fenaux P, et al. (1996) Timed sequential chemotherapy for advanced acute myeloid leukemia. Hematol Cell Ther 38: 161-167
8. Archimbaud E, Jehn U, Thomas X, et al. (1996) A randomized comparison of idarubicin vs mitoxantrone, in association to VP-16 and cytarabine for induction/consolidation therapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia (AML). Br J Haematol 93 [Suppl 2]: 133-134
9. Arlin ZA, Silver R, Cassileth P, et al. (1985) Phase I-II of mitoxantrone in acute leukemia. Cancer Treat Rep 69: 61-64
10. Arlin Z, Case DC, Moore J, et al. (1990) Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Leukemia 4: 177-183
11. Benjamin RS (1995) Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 22 [Suppl 1]: 11-13
12. Bezwoda WR, Bernasconi C, Hutchinson RM, et al. (1990) Mitoxantrone for refractory and relapsed acute leukemia. Cancer: 418-422
13. Bishop JF, Lowenthal LM, Joshua D, et al. (1990) Etoposide in acute nonlymphocytic leukemia. Blood 75: 27-32
14. Bishop JF, Matthews JP, Young GA, et al. (1996) A randomized study of high-dose cytarabine induction in acute myeloid leukemia. Blood 87: 1710-1717
15. Björkholm M, Björnsdottir J, Stenke L, et al. (1990) Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia. Oncology 47: 112-114
16. Bjorkholm M, Liliemark J, Gahrton G, et al. (1995) Mitoxantrone, etoposide and ara-C versus doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukemia. A randomized comparison. Eur J Haematol 55: 19-23
17. Bow EJ, Sutherland JA, Kilpatrick MG, et al. (1996) Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol 14: 1345-1352
18. Brito-Babapulle F, Catovsky D, Newland AC, et al. (1987) Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxantrone. Semin Oncol 14 [Suppl 1]: 51-52
19. Burnett AK, Goldstone AH, Stevens R, et al. (1996) Allo and auto BMT reduce relapse risk in AML in CR1 but do not significantly improve overall survival: results of the MRC AML10 trial. Br J Haematol 93 [Suppl 2]: 313a
20. Carey RW, Ribas-Mundo M, Ellison RR, et al. (1975) Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine or daunorubicin in acute myelocytic leukemia. Cancer 36: 1560-1566
21. Castaigne S, Archimbaud E, Bordessoule D, et al. (1996) Sequential induction or double induction chemotherapy increase didease free survival compared to "3 + 7" chemotherapy in less than 50 years adults with acute myeloid leukemia (AML). Blood 88 [Suppl 1]: 291a
22. Chandrasekaran B, Dimling J, Capizzi RL (1987) Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin. Cancer Treat Rep 71: 195-196
23. Coccia-Portugal MA, Falkson G, Uys A (1990) Mitoxantrone in the treatment of acute leukemia. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Haematology and blood transfusion. Acute leukemias II, prognostic factors and treatment strategies, vol. 33. Springer, Berlin Heidelberg New York, pp. 318-321
24. Crossley RJ (1984) Clinical safety and tolerance of mitoxantrone. Semin Oncol 11 [Suppl 1]: 54-58
25. Daenen S, Löwenberg B, Sonneveld P, et al. (1994) Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Leukemia 8: 6-10
26. Durr FE (1988) Biochemical pharmacology and tumor bioiogy of mitoxantrone and ametantrone. In: Lown JW (ed) Anthracycline and anthracenedione-based anticancer agents. Elsevier, Amsterdam, pp. 163-171
27. Dutcher JP, Wiernik PH, Strauman JJ, et al. (1985) Mitoxantrone (mitox) and cytosine arabinoside (ara-C) in acute nonlymphocytic leukemia (ANLL) and blast crisis of chronic myelogenous leukemia (CML-B). Proc Am Soc Clin Oncol 4: 170a
28. Ehninger G, Proksch B, Heinzel G, et al. (1986) Clinical pharmacology of mitoxantrone. Cancer Treat Rep 70: 1373-1378
29. Ehninger G, Fackler-Schwalbe E, Freund M, et al. (1990) Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Haematology and blood transfusion. Acute leukemias II, prognostic factors and treatment strategies, vol. 33. Springer, Berlin Heidelberg New York, pp. 316-317
30. Estey EH, Keating MJ, McCreadie KB, et al. (1981) Phase I-II study of dihydroxyanthracenedione (DHAD) in acute leukemia (AL). Proc Am Soc Cancer Res 22: 490a
31. Estey EH, Keating MJ, McCredie KB, et al. (1983) Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep 67: 389-390
32. Feldman EJ, Alberts DS, Arlin Z, et al. (1993) Phase II clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 11: 2002-2009
33. Feldman E, Seiter K, Linker C, et al. (1995) Intensive induction without consolidation in elderly patients with newly diagnosed acute myeloid leukemia (AML). Proc Am Soc Clin Oncol 14: 335a
34. Fujimoto S, Ogawa M (1982) Antitumor activity of mitoxantrone against murine experimental tumors: Comparative analysis against various antitumor antibiotics. Cancer Chemoter Pharmacol 8: 157-161
35. Goldberg J, Gryn J, Raza A, et al. (1993) Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia mtergroup study. Am J Hematol 43: 286-290
36. Greidanus J, De Vries EGE, Mulder NH, et al. (1989) A phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone. J Clin Oncol 7: 790-797
37. Haas R, Ho AD, Del Valle F, et al. (1993) Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia. Semin Oncol 20: 20-26
38. Harousseau JL, Milpied N, Brière J, et al. (1990) Mitoxantrone and intermediate-dose cytarabine in relapsed or refractory acute myeloblastic leukemia. Nouv Rev Fr Hematol 32: 227-230
39. Henderson BM, Dougherty WJ, James VC, et al. (1982) Safety assessment of a new anticancer compound, mitoxantrone, in Beagie dogs; comparison with doxorubicin. I. Clinical observations. Cancer Treat Rep 66: 1139-1143
40. Hiddemann W, Kreutzmann H, Straif K, et al. (1987) Phase I/II trial of high-dose cytosine arabinoside and mitoxantrone in adult refractory acute myeloid leukemia. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Haematology and blood transfusion. Acute leukemias II, prognostic factors and treatment strategies, vol. 30. Springer, Berlin Heidelberg New York, pp. 336-338
41. Hiddemann W, Aul C, Maschmeyer G, et al. (1991) High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. Semin Hematol 28: 35-38
42. Hiddemann W, Aul C, Maschmeyer G, et al. (1993) High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. Leuk Lymphoma 10: 133-137
43. Ho AD, Lipp T, Ehninger G, et al. (1988) Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia. An active and well-tolerated regimen. J Clin Oncol 6: 213-217
44. Isnard F, Laporte JPh, Chéron N, et al. (1996) Treatment of acute myelogenous leukemia (AML) in adult patients: a global approach improves the feasibility of bone marrow transplantation (BMT) as well as long term results. Br J Haematol 93 [Suppl 2]: 222a
45. James V, Chicarelli F, Dougherty W, et al. (1983) Preclinical toxicology studies on mitoxantrone and bisantrene. In: Rozencweig M, et al. (eds) New anticancer drugs: mitoxantrone and bisantrene. Raven, New York, pp. 47-69
46. Kano Y, Suzuki K, Akutsu M, et al. (1992) Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line. Leukemia 6: 440-445
47. Keskin A, Tombuloglu M, Atamer MA, et al. (1994) Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia. Acta Haematol 92: 14-17
48. Khalil A, Ciobanu N, Sparano JA, et al. (1995) Pilot study of high-dose mitoxantrone and busulfan plus autologous bone marrow transplantation in patients with advanced malignancies. Bone Marrow Transplant 15: 93-97
49. Knauf WU, Berdel WE, Ho AD, et al. (1994) Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia. Leuk Lymph 12: 421-425
50. Laporte JP, Gorin NC, Lemonnier MP, et al. (1988) A new combination of two intercalating agents (mitoxantrone + daunomycin) in adult refractory acute leukemia: the DON protocol. Cancer Chemother Pharmacol 22: 344-347
51. Larson RA, Daly KM, Choi KE, et al. (1987) A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. J Clin Oncol 5: 391-397
52. Lazzarino M, Morra E, Alessandrino EP, et al. (1989) Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia. Eur J Haematol 43: 411-416
53. Liang R, Chiu E, Chan TK, et al. (1991) Salvage chemotherapy containing moderate-dose cytosine arabinoside and mitoxantrone for relapsed and resistant acute myeloid leukaemia. Cancer Chemother Pharmacol 28: 74-76
54. Liang R, Chan TK, Chu YC, et al. (1995) Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone. Anti-Cancer Drugs 6: 224-228
55. Link H, Freund M, Diedridi H, et al. (1990) Mitoxantrone, cytosine arabinoside and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia. In: Buchner T, Schellong G, Hiddemann W, Ritter J (eds) Haematology and blood transfusion. Acute leukemias II, prognostic factors and treatment strategies, vol. 33. Springer, Berlin Heidelberg New York, pp. 322-325
56. Liu Yin JA, Johnson PRE, Davies JM, et al. (1991) Mitoxantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Hematol 79: 415-420
57. Löwenberg B, Fiere D, Zittoun R, et al. (1991) Mitoxantrone versus daunorubicin in aduction of acute myelogenous leukemia elderly patients and low-dose ara-c vs control as maintenance. An EORTC phase II trial (AML-9). Haematologica 76 [Suppl 4]: 91
58. Lown JW, Hanstock CC, Bradley RD, et al. (1984) Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy. Mol Pharmacol 25: 178-184
59. MacCallum PK, Davis CL, Rohatiner AZS, et al.(1993) Mitoxantrone and cytosine arabinoside as treatment for acute myelogenous leukemia (AML) at first recurrence. Leukemia 7: 1496-1499
60. MacCallum PK, Robatiner AZS, Davis CL, et al.(1995) Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients. Ann Hematol 71: 35-39
61. Marie JP, Zittoun R, Sikic BI (1991) Multidrug resistance (MDR1) gene expression in adult leukemia: correlation with treatment outcome and in vitro drug sensitivity. Blood 78: 586-592
62. Marie JP, Helou C, Thevenin D, et al. (1992) In vitro effect of P-glycoprotein (P-gp) modulators on drug sensitivity of leukemic progenitors (CFU-L) in acute myeloid leukemia (AML). Exp Hematol 20: 565-568
63. Marie JP, Wdowick T, Bisserbe S, et al. (1992) Cost of complete remission induction in acute myeloblastic leukemia: evaluation of the cost-effectiveness of a new drug. Leukemia 7: 720-722
64. Martiat P, Ghilain JM, Ferrant A, et al. (1990) High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study. Eur J Haematol 45: 164-167
65. Masoaka T, Shibata H, Oguma S, et al. (1985) A phase II study of mitoxantrone in acute leukemia. Invest New Drugs 3: 197-201
66. Mayer RJ, Davis RB, Schiffer CA, et al. (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331: 896-903
67. McCauley DL (1992) Treatment of adult acute leukemia. Clin Pharmacol 11: 767-796
68. Meyer P, Ho AD, Ehninger G, et al. (1985) Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Nijhoff, The Netherlands, pp. 203-206
69. Moore JO, Olsen GA (1984) Mitoxantrone in the treatment of relapsed and refractory acute leukemia. Semin Oncol 11 [Suppl 1]: 41-46
70. Murdock KC, Child RG, Fabio PF, et al. (1979) Antitumor agents. I. 1,4-bis[(aminoalkyl)amino]-9,10-anthracenediones. J Med Chem 22: 1024-1030
71. O'Brien S, Kantarjian H, Estey E, et al. (1991) Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia. Cancer 67: 691-694
72. Ohno R, Yokomaku S, Okumura M, et al. (1990) Intensive induction therapy with behenoyl cytosine arabinoside, daunorubicin and 6-mercaptopurine followed by intensive consolidation with mitoxantrone, etoposide, vincristine and intermediate-dose continuous cytarabine (M-85 protocol) for adult myelogenous leukemia. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Haematology and blood transfusion. Acute leukemias II, prognostic factors and treatment strategies, vol. 33. Springer, Berlin Heidelberg New York, p. 304-308
73. Paciucci PA, Cuttner J, Holland JF (1984) Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Semin Oncol 11 [Suppl 1]: 36-40
74. Paciucci PA, Dutcher JP, Cuttner J, et al. (1987) Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. Leukemia 1: 565-567
75. Paciucci PA, Cuttner J, Holland JF (1990) Sequential Intermediate-Dose Cytosine Arabinoside and mitoxantrone for patients with relapsed and refractory acute myelocytic leukemia. Am J Hematol 35: 22-25
76. Paciucci PA, Davis RB, Holland JF, et al. (1990) Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia. Am J Clin Oncol 13: 516-519
77. Pavlovsky S, Gonzalez Llaven J, et al. (1994) A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia. Ann Hematol 69: 11-15
78. Prentice HG, Robbins G, Ma DF, et al. (1984) Mitoxantrone in relapsed and refractory acute leukemia. Semin Oncol 11 [Suppl 1]: 32-35
79. Rodriguez-Morales A, Lopez JL, Sanchez P, et al. (1991) Mitoxantrone (MTZ) and ARA-C high remission rate as first line therapy for acute myeloid leukemia (AML). Haematologica 76 [Suppl 4]: 127a
80. Rowe JM, Mazza JJ, Hines JD, et al. (1990) Mitoxantrone and etoposide in patients with relapsed and refractory acute non-lymphocytic leukemia. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Haematology and blood transfusion. Acute leukemias II, prognostic factors and treatment strategies, vol. 33. Springer, Berlin Heidelberg New York, p. 327-329
81. Samir Motawy M, Salfiti R, Khalifa F, et al. (1989) Experience with combinations containing mitoxantrone in the treatment of adult acute leukemias. J Chemother 1: 123-127
82. Schleyer E, Kamischke A, Kaufmann CC, et al. (1994) New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. Leukemia 8: 435-440
83. Seiter K, Feldman E, Beer M, et al. (1995) Phase II study of high dose mitoxantrone based induction therapy in patients with acute myeloid leukemia. Blood 86 [Suppl 1]: 780a
84. Shenkenberg TD, Von Hoff DD (1986) Mitoxantrone, a new anticancer drug with significant clinical activity. Ann Intern Med 105:67-81
85. Sheperd JD, Barnett MJ, Brockington DA, et al. (1995) Induction and consolidation therapy with intermediate-dose cytarabine, mitoxantrone and etoposide in patients > 60 years with acute myeloid leukemia (AML). Blood 86 [Suppl 1]: 522a
86. Smyth JF, MacPherson JS, Warrington PS, et al. (1986) The clinical pharmacology of mitoxantrone. Cancer Chemother Pharmacol 17: 149-152
87. Solary E, Witz B, Caillot D, et al. (1996) Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 88: 1198-1205
88. Spadea A, Petti MC, Fazi P, et al. (1993) Mitoxantrone, etoposide and intermediate-dose ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia. Leukemia 7: 549-552
89. Tewey KM, Chen GL, Nelson EM, et al. (1984) Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259: 9182-9187
90. Ungerleider RS, Pratt CB, Vietti TJ, et al. (1985) Phase I trial of mitoxantrone in children. Cancer Treat Rep 69: 403-407
91. Valdivieso M, Bedikian AY, Burgess MA, et al. (1981) Phase I clinical study of dihydroanthracenedione administered on a 5 days IV schedule. Cancer Treat Rep 65: 841-844
92. Van Echo DA, Shulman PN, Ferrari A, et al. (1982) A phase II trial of mitoxantrone (DHAD, NSC-301739) in adult acute leukemia. Proc Am Soc Clin Oncol 1: 132a
93. Vietti TJ, Steuber P, Kim TH, et al. (1983) Mitoxantrone in children with malignant disease. In: Rozencweig M, Von Hoff DD, Staquet MJ (eds) New anticancer drugs: mitoxantrone and bisantrene. Raven, New York, pp. 93-102
94. Visani G, Petti MC, Cenacchi A, et al. (1995) MEC (mitoxantrone, etoposide and intermediate-dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia. Leuk Lymph 19: 447-451
95. Vredenburgh JJ, McIntyre OR, Cornwell II GG, et al. (1988) Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. Med Pediatr Oncol 16: 187-189
96. Wahlin A, Hörnsten P, Hedenus M, et al. (1991) Mitoxantrone and cytarabine versus daunorubicin and cytarabine in previously untreated patients with acute myeloid leukemia. Cancer Chemother Pharmacol 28: 480-483
97. Walters RS, Kantarjian HM, Keating MJ, et al. (1988) Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 62: 677-682
98. Wattel E, Solary E, Caillot D, et al. (1996) Quinine improves results of intensive chemotherapy in myelodysplastic syndromes (MDS) expressing P glycoprotein (PGP). Blood 88 [Suppl 1]: 455a
99. Wells RJ, Odom LF, Gold SH, et al. (1994) Cytosine arabinoside and mitoxantrone treatment of relapsed or refractory childhood leukemia: initial response and relationship to multidrug resistance gene 1. Med Pediatr Oncol 22: 244-249
100. Wheatley K (1995) Meta-analysis of randomized trials of idarubicin (IDAR) or mitoxantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukaemia (AML). Blood 86 [Suppl 1]: 434a
101. Zbinden G, Beilstein AK (1982) Comparison of cardiotoxicity of two anthracenediones and doxorubicin in rats. Toxicol Lett 11: 289-297
102. Zittoun R, Mandelli F, Willemze R, et al. (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332: 217-223